Day 1 :
- Vaccines
Session Introduction
Gowhar Ahmad
University of Kashmir, India
Title: Squint causes types management and scenerio of bilateral medial rectii recessions as a surgical modalities for bilateral alternating infantile esotropia in cases of six months old male twins
Biography:
Gowhar Ahmad is Sr. Consultant Ophthalmologist, Florence hospital, Chanapora Srinagar Kashmir, India. He has done MBBS MS ophthalmology fellowship in pediatric ophthalmology from Moorfields Eye Hospital, London, fellowship in oculoplasty and neurophthmology from King Khaled Eye Specialist Hospital-Riyadh, Saudi Arabia. He has more than 40 years of experience in the field of ophthalmology. He is a National and international speaker, has many international publications on JOJO and MSOR posted more than 17000 and b1700 articles on Docplexus and LinkedIn respectively till dat. He is an influencer on Curofy, Icon Curofy of year 2021. He is an Editor in chief international journal of scientific research, member scientific committee of world congress of clinical pediatrics and neonatology member, scientific committee of world congress of d m and pediatric endocrinology, member international journal of ophthalmology and advanced research, reviewer researcher and board member of many international journals has attended many international webinars as speaker member KOS Ophthalmic society.
Abstract:
Squint is a very common Occular condition characterized by abnormal occular deviations with absence of normal Occular paralesum and paucity of binocular vision which is kind of Simultaneous perception, Simultaneous fusion and stereopsis. Main aim of squint management is not only to correct the abnormal occular deviation but to ensure normal' visual status. For this early and prompt diagnosis and management is very important so it is very important for every parent to seek the advice of pediatric ophthalmologist if they observe any abnormal occular deviations of their kids. In past in underdeveloped Asian countries squint was considered to be a kind of stigma especially in girls, So by the time they were shown to ophthalmologist amblyopia had already been in action so treatment was only cosmetic squint correction. However at present with better education and awareness prognosis of squint is very good. Since we have different Ophthalmic subspecialists 3 basic things have to be done in every case of squint VA assessment, Mydriatic refraction and fundus examination because we have some occular conditions like Retinoblastoma and coats disease which cause squint Can be commitant in commutant, Accommodative non accommodative, Paralytic non paralytic, bilateral alternating infantile esotropia, Paralytic squint presents as diminishing of vision impairment of occular movements diplopia turning the head towards the direction of action of paralysed muscle. Primary deviation is greater than sec deviation false orientation false perception abnormal head tilt ocular torticollis vertigo, bilateral alternating infantile, ESOTROPIA presents as Crossed fixation, uncrossed fixation, Broad angle, Av pattern. Covering the dominant eye will make child to cry. 6 months old male twins were seen by me in my clinic some time ago with parents having noticed bilateral inward occular deviations of both eyes both twins full term normally delivered make twins no history of exposure to oxygen or jaundice no other Cong abnormalities. In exam both twins had bilateral alternating infantile esotropia of 20 to 25 degrees, VA assessment mydriatic refraction and fundus examination was normal. So under BILTERAL 5 mm medial recti recessions was done. Since we do not cut muscles so this procedure not only ensures a good correction of angle of squint but eye reaction is minimal.
Anil Batta
MM Institute of Medical Sciences & Research, India
Title: Clinical applications of DNA vaccines: Current progress
Biography:
Anil Batta is presently professor & Head with senior consultant in Govt. Medical College, Amritsar. He did his M.B.B.S. and M.D. in Medical Biochemistry from Govt. Medical College, Patiala in 1984 and 1991, respectively. His research interest is mainly in clinical application especially cancer and drug de-addiction. He has supervised more than 25 M.D., M.Sc. and Doctorate researches and published more than 130 international research papers. He is the chief editor of America’s Journal of Biochemistry. He is also working as advisor to the editorial board of International Journal of Biological and Medical Research. He has been deputed member Editorial Board of numerous International & National Medical Journals of Biochemistry. He has also been attached as technical advisor to various national and international conferences in Biochemistry. He has been attached as hi-tech endocrinal, genetics and automated labs of Baba Farid Univ. of Health Sciences, Faridkot. He has chaired various sessions in the Biochemistry meets. He has been designated as member Editorial Board of various in US and other European Countries. He is also involved in various research projects at Govt. Medical, Amritsar. He has done superspecialisation in Drug-de-addiction from PGIMER, Chandigarh.
Abstract:
It was discovered almost 20 years ago that plasmid DNA, when injected into the skin or muscle of mice, could induce immune responses to encoded antigens. Since that time, there has since been much progress in understanding the basic biology behind this deceptively simple vaccine platform and much technological advancement to enhance immune potency. Among these advancements are improved formulations and improved physical methods of delivery, which increase the uptake of vaccine plasmids by cells; optimization of vaccine vectors and encoded antigens; and the development of novel formulations and adjuvants to augment and direct the host immune response. The ability of the current, or second-generation, DNA vaccines to induce more-potent cellular and humoral responses opens up this platform to be examined in both preventative and therapeutic arenas. This review focuses on these advances and discusses both preventive and immunotherapeutic clinical applications.
Zakaria Benmansour
University of Es Senia, Algeria
Title: COVID -19 diagnostic and therapeutic management of HCV at the CHU Oran
Time : 13:10-13:30
Biography:
Zakaria Benmansour is a doctor in University of Medical Sciences "Oran Algeria On parasitology and mycology medical" Laboratory of The University Hospital, Oran. He is a researcher in the laboratory of infectious diseases and biologically active substances in the faculty of medicine of Oran Algeria. His research work focuses on molecular fungal and virology and vaccinology. He has done PhD in parasitology and mycology department of medicine of Oran Algeria. His research included work on mycology and parasitology infections.
Abstract:
Hepatitis C Virus (HCV) is a major cause of chronic liver disease all over the world. It was discovered in 1975 that most instances of transfusion-related hepatitis were not associated with hepatitis A or Hepatitis B Virus (HBV) infections and hence named the condition non-A, non-B hepatitis. HCV infection has been linked to acute and chronic hepatitis, as well as liver cancer. In December 2019, the health authorities in the Chinese city of Wuhan, in the province of Hubei, announced the outbreak of a previously unknown acute pneumonia-like coronavirus infection, caused by SARS CoV-2. The commonest presentation included fever, cough, sore throat, fatigue/bodily pains, vomiting, diarrhea, nausea, shortness of breath. This study aimed to explore the prevalence of Hepatitis C Virus (HCV) and SARS CoV-2 (COVID-19) in suspected patients in Western Algeria. Quantitative Polymerase Chain Reaction (PCR) test was conducted for samples for both Hepatitis C Virus (HCV) and SARS CoV-2 (COVID-19). The experiment was carried out in the central laboratory of the hospital establishment of the University of Oran over a period of 4 weeks (1 month) during which results were documented. At the end of the experiment, it was observed from results that majority of the patients (104/159) that tested for HCV tested positive, while majority (63/69) also tested negative for COVID-19. From the current study, it can be ascertained that COVID-19 is no longer prevalent in this day and age unlike it was when the virus initially broke.
Chalelgn Kassaw Belete
Addis Ababa University, Ethiopia
Title: Acceptance of booster dose of COVID-19 vaccine and its determinants among health care workers at Tikur Anbessa specialized hospital
Biography:
Chalelgn Kassaw Belete is affiliated to the Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Ethiopia.
Abstract:
Background: A COVID-19 Vaccine Booster Dose was designed to restore protection in those who initially took immunization series. Nevertheless, the acceptance level has been low even by healthcare workers. Thus, this study aimed to assess the level of acceptance COVID-19 vaccine Booster Dose and its determinants among healthcare workers.
Methodology: A cross-sectional study with convenient sampling technique and self-administered questionnaire was followed to collect data among 423 healthcare workers at Tikur Anbessa Specialized Hospital May to June 2022.
Results: Of 399 participants who completed the response, 80.5%, 60.2% and 51.4% of them were health professionals, in the age group of 18-30 years and males, respectively. Over half (53.7%) of them had no COVID-19 infections history. The majority (81.2%) took at least two doses of the COVID-19 vaccines. Less than one-third (28.6%) of the respondents accepted the Booster. Majority of them (86.5%) had a favorable attitude towards the Booster. The odds of Booster Dose acceptance were higher in age 31-40 (AOR=2.21; 95% CI,1.13-5.13), age 41-50 (AOR=4.14; 95% CI,1.64-15.51), age above 50 (AOR=6.00; 95% CI,2.18–16.59), in married (AOR=1.82; 95% CI 1.02-3.25), infection history after vaccinations (AOR=1.94; 95% CI,1.08-3.48) and having favorable attitude (AOR=16. 74; 95% CI,3.78-74.09).
Conclusion: The acceptance level of the COVID-19 Booster dose was low. Age, being married, COVID-19 infection history and favorable attitude were the determinants of the Booster Dose acceptance.